Latest Kyowa Kirin News & Updates

See the latest news and media coverage for Kyowa Kirin. We track all announcements, press releases, and industry mentions in real time, all in one place.

Kyowa Kirin

Japan-based global specialty pharmaceutical company

kyowakirin.com

Headquarters: Chiyoda-ku, Japan
Company type: Public company
Number of employees: 5,000–10,000
Industry: Pharmaceuticals

Last updated October 7

Latest news about Kyowa Kirin

In short: Kyowa Kirin posted strong H1 2026 results and FDA accepted its achondroplasia drug infigratinib, while rocatinlimab trials were discontinued.

Company announcements

August 21 Kyowa Kirin

Kyowa Kirin integrates its CDXO role into the CSO position

This restructuring accelerates digital transformation and AI adoption as core growth drivers under new leadership starting October 1, 2026

July 13 Kyowa Kirin

Kyowa Kirin announces CEO transition

Chairman Masashi reflects on global expansion while CEO Abdul commits to building a Super Team.

July 2 Kyowa Kirin

Kyowa Kirin highlights publication of Phase 3 infigratinib trial in NEJM

The PROPEL 3 study met its primary endpoint and showed significant height velocity improvement in children with achondroplasia.

June 30 Kyowa Kirin

Kyowa Kirin selected for FDA PreCheck Pilot Program

The program aims to accelerate manufacturing timelines and enhance supply chain resilience at its new Sanford, NC facility.

Media coverage

October 7 日刊薬業

Pediatric achondroplasia drug, FDA accepts application

Kyowa Kirin announced on the 7th that its oral FGFR1-3 inhibitor "KK8398" (development code, generic name = infigratinib) had its new drug application for treatment of pediatric achondroplasia accepted by the U.S. FDA (Food and Drug Administration)... Regarding viewing restrictions for non-members This article is for members only...

September 1 Nikkei

Kyowa Kirin stock continues to fall; new drug candidate fails to meet primary endpoint in clinical trial

(12:30, Prime, Code 4151) Kyowa Kirin is continuing to fall. In the morning session, it hit a price of 2,183 yen, down 180 yen (7.61%) from the previous day. It remains lower in the afternoon session. On the 8th, in the Phase 2 international clinical trial for the new eye drop drug candidate 'KHK4951' targeting neovascular age-related macular degeneration...

August 30 Bloomberg

Trump US administration reaches agreement on drug prices with nine pharmaceutical companies - including Astellas and Kyowa Kirin

The Trump US administration has reached an agreement with nine biotechnology and pharmaceutical companies, including UCB, BridgeBio Pharma, and San Pharmaceutical Industries, regarding new drug pricing. Japanese companies Astellas Pharma and Kyowa Kirin have joined the agreement...

August 12 Nikkei

Kyowa Kirin, increased revenue and profit

[Increased revenue and profit] Sales of key products such as the rare bone disease treatment 'Crysvita' have been strong. Due to the discontinuation of development of the atopic dermatitis treatment 'Rocatinlimab', a one-time contract-related payment from the co-developing U.S. company was recorded in full. ... To the email address you registered ...

Never miss news about Kyowa Kirin

Track Kyowa Kirin and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Kyowa Kirin competitors & trending companies

Browse news for competitors to Kyowa Kirin and other trending companies.